To determine maternal serum concentrations of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) longitudinally in normal pregnancies, pregnancies that developed preeclampsia and pregnancies that deliver a small for gestational age (SGA) infant, in order to evaluate them as markers for the prediction of preeclampsia.
In this case–control study we included 12 singleton pregnancies that developed preeclampsia and 104 randomly selected singleton normal pregnancies. Fourteen of the normal pregnancies gave birth to an SGA infant. Blood samples and ultrasonographic data were collected during the 1st, 2nd and 3rd trimesters of pregnancy.
In preeclamptic pregnancies, PlGF (pg/mL) (median; inter-quartile range) was significantly lower in the 2nd (208; 84–339) (p = 0.035) and in the 3rd trimester (202; 109–284) (p = 0.002) while sFlt-1 was significantly higher only in the 3rd trimester (2521; 2101–3041) (p = 0.011) compared to normal pregnancies (PlGF 2nd: 311; 243–440, PlGF 3rd: 780; 472–1037, sFlt-1 3rd: 1616; 1186–2220). In pregnancies with SGA infants, PlGF and sFlt-1 did not differ significantly from normal pregnancies in any trimester. The sFlt-1 to PlGF ratio was significantly higher in preeclamptic pregnancies than in normal pregnancies, in both the 2nd and 3rd trimesters. The relative difference and the slope of PlGF concentration between 1st and 2nd trimester were significantly reduced in preeclampsia compared to normal pregnancies. A logistic regression model with predictors BMI, 2nd trimester Doppler PI and relative difference of PlGF from the 1st to the 2nd trimester gave 46% sensitivity and 99% specificity for the prediction of preeclampsia, with a very high negative predictive value of 98.3%.
Our study confirms that maternal serum PlGF concentration is significantly lower, at least after 20th week, while sFlt-1 concentration is significantly higher in 3rd trimester, in pregnancies destined to develop preeclampsia. Pregnancies that gave birth to SGA infants do not have altered angiogenic factor concentrations throughout pregnancy. The relative difference of PlGF from the 1st to the 2nd trimester, uterine artery Doppler PI in the 2nd trimester and BMI are the most powerful markers for the prediction of preeclampsia.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002.Int J Gynaecol Obstet. 2002; 77: 67-75
- Preeclampsia–eclampsia in Greece.Hellen Obstet Gynacol. 2003; 15: 37-44
- Pathogenesis of preeclampsia.Annu Rev Pathol. 2010; 5: 173-192
- Preeclampsia and the anti-angiogenic state.Pregnancy Hypertens. 2011; 1: 17-21
- Insights into angiogenic imbalances during pregnancy.Obstet Gynecol. 2009; 114: 437-440
- Circulating angiogenic factors and the risk of preeclampsia.N Engl J Med. 2004; 350: 672-683
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.J Matern Fetal Neonatal Med. 2008; 21: 9-23
- Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.J Clin Endocrinol Metab. 2005; 90: 4895-4903
- The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation.J Matern Fetal Neonatal Med. 2008; 21: 25-40
- Angiogenic factors for the prediction of preeclampsia in high-risk women.Am J Obstet Gynecol. 2007; 197: 244.e1-244.e8
- The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients.Am J Obstet Gynecol. 2012; 206: 58.e1-58.e8
- Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review.Clin Chem. 2010; 56: 361-375
- Centile charts for birthweight for gestational age for Scottish singleton births.BMC Pregn Childbirth. 2008; 8: 5
- Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia.Clin Biochem. 2010; 43: 768-770
- Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?.Am J Obstet Gynecol. 2012; 206: e1-e7
- Early-pregnancy soluble Fas levels in idiopathic small-for-gestational-age pregnancies.Am J Obstet Gynecol. 2010; 202: e1-e7
- First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.J Clin Endocrinol Metab. 2004; 89: 770-775
- Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.Circulation. 2010; 122: 478-487
- Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review.Reprod Biol Endocrinol. 2011; 9: 77
- First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.Am J Obstet Gynecol. 2008; 199: e1-e6
- Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth.Obstet Gynecol. 2007; 109: 1316-1324
- Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.Prenat Diagn. 2010; 30: 191-197
- Serum markers for pre-eclampsia: an update on the analytes to be determined in the first, second, and third trimester.Immuno-Analyse et Biologie Specialisee. 2009; 24: 58-68
- Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia.Ultrasound Obstet Gynecol. 2008; 32: 732-739
- First-trimester placental growth factor as a marker for hypertensive disorders and SGA.Prenat Diagn. 2010; 30: 565-570
- Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.Acta Obstet Gynecol Scand. 2008; 87: 837-842
- Threshold of soluble Fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia.Hypertension. 2011; 58: 859-866
- A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia Prediction of preeclampsia.J Matern Fetal Neonatal Med. 2009; 22: 1021-1038
- Predictive value of angiogenic factors and uterine artery Doppler for early-versus late-onset pre-eclampsia and intrauterine growth restriction.Ultrasound Obstet Gynecol. 2008; 31: 303-309
- Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry.Int J Gynecol Obstet. 2008; 102: 146-151
Published online: September 09, 2013
Accepted: August 23, 2013
Received in revised form: July 24, 2013
Received: February 18, 2013
© 2013 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.